7:00 am
Registration & Coffee
7:50 am Chair’s Opening Remarks
Optimising Delivery to the Tumour Microenvironment
8:00 am Where Next for the Clinical Development of Gamma-Deltas & NK cells?
Synopsis
- Deep-diving into gamma delta and NK cells’ biology and clinical potential to target solid tumours
- Examining the fundamental biology of innate immune cells and the properties that make them unique in their ability to target solid tumours
- Evaluating the clinical data success and failures of NK and gamma delta T cells to fuel further development
- Hear exclusive updates on TC BioPharm’s clinical development
8:30 am Engineering & Analyzing Gamma Delta T cells – Think Translational
Synopsis
- Introducing solutions for your translational gamma delta T cell workflows
- Sharing comprehensive immune cell composition analysis and subset typing
9:00 am Arming Cell Therapies to Override Immunosuppressive Mechanisms & Penetrate Tumours
Synopsis
- Priming patients NK cells with INKmune to initiate successful homing to the tumour microenvironment and elimination of cancer cells
- Reviewing preclinical data of “pseudokine” activity producing the same proteomic effects of combinations of IL12/15/18
- Leveraging clinical data of the clinical responses of “pseudokine” to determine its safety and efficacy
9:30 am Enhancing Homing Strategies to Improve Delivery to Tumours & Prevent Off-Target Toxicity
Synopsis
- Evaluating engineering and co-therapy strategies to direct antibodies and cell therapies to the tumour
- Exploring the delivery of cells intratumorally with a catheter to maximise dose delivery and demonstrate the importance of homing on patient outcomes
- Improving biodistribution of active therapies with cloaking mechanisms
10:00 am
Morning Refreshments & Speed Networking
Fine-Tuning Safety Profiles to Accelerate Clinical Development
11:00 am Gamma Delta T Cells: Manufacturing & Dosing Strategies Based on Biological Understanding to Optimize Therapies & Improve Responses
Synopsis
- Understanding the mechanism of action of gamma delta T cells to support indication selection and repeat dosing
- Optimising manufacturing and dosing to improve potential outcomes and scale-up
- Utilising preclinical data to support entry into the clinic, clinical strategy and current clinical progress to-date
11:30 am Role of Mathematical Modelling in Cell Therapy
Synopsis
- Harnessing modelling and data analysis to drive combination strategy and optimise dose regimens
- Using modelling to inform preclinical study designs and demonstrate preclinical safety and efficacy
- Review Takeda’s future directions and expansion to the clinic
12:00 pm Harnessing Innate Cell Engagers (ICE®) As Mono- & Combination Therapy to Induce Innate Immune Cell-Mediated Tumour Elimination with Favourable Safety Profiles
Synopsis
- Outlining the mechanism behind Affimed’s innate cell engagers and their ability to tailor therapies to specific patient populations
- Showcasing clinical data from the lead candidate AFM13 in combination with cord blood-derived NK cells in patients with r/r CD30-positive lymphoma
- Providing phase 1 trial data on AFM24 in solid tumours and discussing the potential for combination with cell therapy
- Highlighting pre-clinical efficacy results for AFM28 in combination with NK cells, that substantiate the rationale to develop this candidate for patients in need of novel approaches
12:30 pm
Lunch & Networking
Unravelling the Mechanism of Action to Supercharge Combination Therapy Development
1:30 pm Determining the Anti-Tumoral Activity of BAY 3375968: An Afucosylated Anti-CCR8 Antibody Which Depletes Activated Intratumoral Tregs via the Innate Immune System to Kill Cancer
Synopsis
- Understanding Treg promotion of cancer by suppressing the function of CD8+ and CD4+ T cells in the TME to hamper the efficacy of immune checkpoint inhibitors
- Harnessing BAY 3375968 by simultaneous binding to CCR8 on Tregs and to Fcγ receptors on effector cells to induce ADCC and ADCP to mediate the cancer kills
- Utilising assays and preclinical models to characterize the MOA of anti-tumour action of BAY 3375968 and mouse CCR8 surrogate antibodies in vitro and in vivo for smooth translation to the clinic
2:00 pm Cancer Immunotherapy Using Bispecific γδ-T Cell Engagers
Synopsis
- Elucidating the mechanism of action of bispecific γδ-T cell engagers
- Sharing preclinical work that indicates the therapeutic potential to treat haematological and solid malignancies
- Providing insight in trial design and first clinical data obtained from bispecific γδ-T cell engagers
2:30 pm Developing a Non-Alpha IL-2 as a Single Agent & Potential Combination Partner to Potentiate NK-Cell Based Therapies
Synopsis
- A pre-clinical description of the molecule, and early work to optimize non-alpha IL-2 using non-natural DNA base pairing
- Presenting early clinical toxicity and efficacy data showing non-alpha IL-2 may minimise toxicity and maximise clinical efficacy in a single agent setting
- Elucidating future potential combination strategies for non-alpha IL-2, including NK cell therapy and NK cell engager molecules
3:00 pm Developing In Vivo & In Vitro Models for iNKT-Based Cell Therapies & Checkpoint Combinations
Synopsis
- Developing adoptive transfer models for human and murine iNKT cells to demonstrate iNKT cell therapy proof-of-concept
- Generating models to assess the impact of checkpoint antibodies on iNKT cell therapy for future combinations
- Understanding the pros and cons of combination therapies, and MiNK Therapeutics’ future strategy
3:30 pm
Afternoon Refreshments & Poster Session
Knocking Down Investment Hurdles
4:00 pm Sharing an Overview of the Current Developments, Clinical Trials & Key Players in the European Clinical Trial Landscape
Synopsis
- Providing a comprehensive analysis of antibody and cell-based trials
- Highlighting clinical trial hotspots in Europe to identify key areas for European development
- Reviewing innate immune therapy in the context of the current IO and cell therapy landscape, and future trends
4:30 pm Panel Discussion – Driving Down the Cost of Innate Immune Therapeutic Development in Europe to Match US Development
Synopsis
- Understanding the early aspects of cell therapy business building from financing, investment, market dynamics and sourcing
- Painting the reimbursement map for Europe and the US, and the registration of use by UK healthcare services to streamline clinical development
5:00 pm Roundtable Discussions – Reimbursement & Market Strategy in the EU
Synopsis
Practical and highly interactive breakout-style roundtables where attendees can crowd-source solutions and share their opinions around reimbursement and commercialisation. This is a valuable opportunity for you to voice your experiences and debate best practice while identifying unique solutions.